Please ensure Javascript is enabled for purposes of website accessibility

COVID Vaccine Stocks: How Strong Is BioNTech's Financial Position?

By Keith Speights - Jan 25, 2021 at 9:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The German biotech appears to be in pretty good shape.

BioNTech (BNTX 1.32%) has now hit the big time. Its first approved product, COVID-19 vaccine BNT162b2, is on its way to quickly becoming a mega-blockbuster success for the biotech. But how strong is BioNTech's financial position right now?

In this Motley Fool Live video recorded on Jan. 13, 2021, Healthcare and Cannabis Bureau Chief Corinne Jurney Cardina and Fool.com writer Keith Speights looked at the company's cash position and income statement.

Corinne Cardina: What do you think about their [BioNTech's] financials? Do they have enough cash to do all of these trials? Where are they getting their money from?

Keith Speights: We're going to look at that too. Most of their money right now is just coming from collaboration deals, Pfizer and others, as we've seen. Let's take a look at their financials.

I'm going to look at their balance sheet, as we did for Moderna a few minutes ago, and drill into their cash position. Actually, let me change that to quarterly so we can see where they are more recently.

They have a little over one billion dollars in cash as of the end of September, a pretty healthy cash stockpile there, and it's grown. It's nearly doubled since the end of 2019. No surprise there. They've received money from Pfizer. They actually received some money from the European Union, from Germany, because they're based in Germany. They've received some money to help fund their programs, so their cash position has grown dramatically over the course of the last year. Let's say a billion dollars.

How are they looking from a bottom-line standpoint? Well, let's go over to the income statement and take a look. I'm going to change that to quarterly as well. Unfortunately, their bottom line isn't at the bottom line [laughs] in Yahoo's display here.

They lost around $210 million in their last quarter. Over the last 12 months, they've lost a little over 400 million. They're in a great position financially, a billion-dollar cash stockpile. They lost 400 million over the last year, they could go quite a while, and they're about to make a lot more money this year from their COVID vaccine. I think they're in a healthy cash position, but their other candidates are much farther out before they can potentially get to that point of winning approval than Moderna's pipeline is.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioNTech SE Stock Quote
BioNTech SE
BNTX
$134.04 (1.32%) $1.75

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
321%
 
S&P 500 Returns
111%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.